Sinopharm Tech Holdings Limited (8156) AI Stock Analysis

• Market Cap: HK$196.44M
• Dividend Yield: N/A
• Average Volume (3M): 157.92K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.30
• Revenue Growth: 48.39%
• EPS Growth: 88.30%
• Country: HK
• Employees: 30
• Sector: Technology
• Sector Strength: 88
• Industry: Software - Application
• EPS (TTM): >-0.01
• Shares Outstanding: 633,693,050
• 10 Day Avg. Volume: 46,340
• 30 Day Avg. Volume: 157,918
• PEG Ratio: 1.01
• Price to Book (P/B): -2.33
• Price to Sales (P/S): 1.40
• P/FCF Ratio: -11.93
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 48 Neutral
• Price Target: HK$0.31 ▲(39.55% Upside)
• Action: Reiterated Date: 11/25/25
• Date: Action: Reiterated 11/25/25

The overall stock score is primarily impacted by financial performance challenges, including negative equity and profitability issues. While technical analysis shows positive momentum, the valuation remains unattractive due to a negative P/E ratio. The absence of earnings call data and corporate events means these factors do not influence the score.

Positive Factors

Very strong revenue growth

A 224% year surge in revenue signals a substantial top-line recovery and stronger product or market traction. Durable revenue expansion provides room for operating leverage and reinvestment, improving long-term scalability if management sustains customer acquisition and monetization.

Improving free cash flow trends

Notable improvement in free cash flow growth points to progress turning sales into durable cash generation. If the trend persists, it reduces reliance on external financing, supports capital allocation choices and strengthens the company’s ability to invest in product development or scale operations.

Lean, scalable software headcount

A 30-person headcount is consistent with a capital-light, scalable software model where revenue can grow faster than operating costs. Low fixed labor costs support long-term margin expansion potential as sales scale, making profitable operating leverage achievable if growth persists.

Negative Factors

Negative stockholders' equity & high leverage

Negative equity and elevated leverage pose lasting solvency and flexibility risks. This capital-structure weakness can restrict borrowing capacity, increase refinancing risk, and limit strategic investment, leaving the business vulnerable to shocks or higher interest costs over months.

Negative operating cash flow

Persistently negative operating cash flow strains liquidity and forces dependence on external financing or asset sales. Over a multi-month horizon, weak cash generation can limit working capital, capex and product investment, undermining the company’s ability to sustain growth independently.

Persistent unprofitable margins

Negative net and EBIT margins indicate core operations are not yet self-sustaining. Without sustained margin improvement, continued revenue growth may fail to translate into earnings or cash, risking dilution, restructuring needs, or constrained reinvestment over the medium term.

Sinopharm Tech Holdings Limited Business Overview & Revenue Model

Company Description

Sinopharm Tech Holdings Limited, an investment holding company, engages in lottery business in the People's Republic of China and Hong Kong. The company operates through Provision of Lottery-Related Services, Provision of Internet Plus Services, Manufacturing and Distribution of Personal Protective Equipment, and Other Services segments. It offers lottery-related hardware and software systems. The company is also involved in the provision of Internet plus solution services to health care, government affairs, leasing, public security, and other industries; and supply chain management, data analysis, and related services, as well as trading of goods through internet platform. In addition, it offers corporate management services; and distribution of personal protective equipment. The company was formerly known as China Vanguard You Champion Holdings Limited and changed its name to Sinopharm Tech Holdings Limited in June 2019. Sinopharm Tech Holdings Limited was founded in 1999 and is headquartered in Sha Tin, Hong Kong.

How the Company Makes Money

null

Sinopharm Tech Holdings Limited Financial Statement Overview

Summary

Sinopharm Tech Holdings Limited is experiencing strong revenue growth but faces significant profitability and financial stability challenges. The negative equity and high leverage are major concerns, while cash flow improvements offer some hope for recovery.

Income Statement

The company has shown significant revenue growth of 224.12% in the latest year, indicating a strong recovery. However, profitability remains a concern with a negative net profit margin and EBIT margin, reflecting ongoing operational challenges.

Balance Sheet

The balance sheet reveals a negative stockholders' equity, indicating financial instability. The high debt-to-equity ratio suggests significant leverage, posing a risk to financial health. The return on equity is not meaningful due to negative equity.

Cash Flow

Cash flow from operations is negative, which is concerning. However, there is a substantial improvement in free cash flow growth, suggesting potential for future cash generation. The ratios indicate cash flow challenges relative to net income.

Breakdown	Jun 2024	Jun 2023	Jun 2022	Jun 2021	Jun 2020
Income Statement
Total Revenue	61.25M	41.28M	42.84M	40.98M	77.81M
Gross Profit	13.52M	5.02M	5.47M	5.10M	20.88M
EBITDA	6.11M	4.98M	-1.01M	-75.17M	-89.65M
Net Income	-867.00K	-19.70M	-10.63M	-88.00M	-106.34M
Balance Sheet
Total Assets	51.74M	44.49M	33.48M	76.89M	135.90M
Cash, Cash Equivalents and Short-Term Investments	6.95M	2.64M	1.78M	2.99M	7.48M
Total Debt	46.73M	73.26M	53.00M	45.93M	108.03M
Total Liabilities	88.43M	250.09M	213.24M	250.28M	276.46M
Stockholders Equity	-36.87M	-199.48M	-172.73M	-166.78M	-138.88M
Cash Flow
Free Cash Flow	-7.21M	-12.58M	4.73M	-36.88M	-16.32M
Operating Cash Flow	-7.21M	-9.25M	4.73M	-36.76M	-6.21M
Investing Cash Flow	-9.00K	-4.86M	2.00K	-85.00K	-5.05M
Financing Cash Flow	11.50M	14.98M	-4.52M	32.24M	12.46M

Sinopharm Tech Holdings Limited Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.22
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:8156, the sentiment is Positive. The current price of 0.22 is below the 20-day moving average (MA) of 0.29, below the 50-day MA of 0.30, and below the 200-day MA of 0.27, indicating a bullish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 55.52 is Neutral, neither overbought nor oversold. The STOCH value of 75.19 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:8156.

Sinopharm Tech Holdings Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
8100	72 Outperform	HK$140.00M	-4.85	-2.72%	0.57%	-13.40%	76.97%
Sector *	61 Neutral	$37.18B	12.37	-10.20%	1.83%	8.50%	-7.62%
8156	48 Neutral	HK$196.44M	-12.91	―	―	48.39%	88.30%
8071	47 Neutral	HK$117.15M	-18.45	-43.83%	―	-49.86%	15.00%
8036	44 Neutral	HK$32.41M	15.56	-0.42%	―	-14.25%	77.78%
8131	44 Neutral	HK$52.74M	6.10	-523.99%	―	78.40%	72.37%
8290	44 Neutral	HK$56.00M	-105.56	-2.07%	―	-6.88%	-100.00%